Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that the combination of a 308-nm excimer lamp and 10% liquor carbonis detergens significantly improved scalp psoriasis symptoms compared to the excimer lamp alone, with more patients achieving 75% reduction in their Psoriasis Scalp Severity Index.

This report details a case study where a 40-year-old woman experienced allergic contact dermatitis and angioedema-like symptoms after using PPD-containing hair dye. Patch testing confirmed a positive reaction to PPD, highlighting the substance's potential to cause both T-cell and IgE-mediated hypersensitivity reactions.

This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

This study observed that erosive pustular dermatosis of the scalp in elderly patients was effectively treated with high-potency topical steroids, with plasma and lymphocyte dermal infiltrates helping to confirm diagnosis.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This review highlights advancements in drug delivery systems for treating psoriasis and atopic dermatitis, focusing on their ability to enhance transdermal drug efficacy and safety by overcoming skin barriers and enabling precise, on-demand drug release at target sites.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

This study analyzed clinical manifestations in 18 dermatomyositis patients, noting that all exhibited skin rash and variable symptoms like itching and muscle weakness, with treatment involving prednisolone and hydroxychloroquine.

This study found that the 15-PGDH inhibitor DPP improved endothelial function in hair-related cells exposed to DHT by reducing oxidative stress and enhancing angiogenic capacity.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.

Dupilumab can cause psoriasis in some patients.

This study found that while DP concentrations in dust were higher in male dormitories, DP in hair was higher in females, suggesting differing metabolism between genders and that hair DP mainly originates internally.

This study found that nano-sized lipid particles improved the skin accumulation and retention of dexamethasone compared to a base cream, suggesting potential benefits for inflammatory skin disease treatment.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

This report describes a woman with borderline lepromatous leprosy who developed a serious skin reaction to dapsone; she recovered quickly after stopping dapsone and receiving corticosteroids.

This study found that treating moderate-to-severe prurigo nodularis with dupilumab significantly improved itch severity, skin condition, and quality of life over 104 weeks, with a favorable safety profile, even in elderly and comorbid patients.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.

Alopecia areata often recurs after treatment with diphenylcyclopropenone.

This study reports that while DCP had similar treatment efficacy in propylene glycol and isopropanol for alopecia areata, the formulation in isopropanol was better tolerated.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

In this study, researchers reported that applying topical 7.5% dapsone led to a significant decline in lichen planopilaris activity within a month and a sustained two-year remission in a patient intolerant to other treatments, suggesting dapsone as a promising alternative for managing this condition.

Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.

Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.

This case report described a 62-year-old woman with dermatomyositis whose multiple subcutaneous nodules persisted despite treatment with prednisone and methotrexate, prompting further dermatological evaluation.